PLC7 Antibody

Definition and Pathophysiological Role

Anti-PL7 antibodies inhibit ThrRS, disrupting tRNA aminoacylation and triggering autoimmune responses. This antibody is linked to:

• Immune dysregulation: ThrRS inhibition activates pro-inflammatory pathways (e.g., JNK), contributing to tissue damage in muscles and lungs .

• Clinical associations: Strong correlation with ILD (≥90% of cases) and milder myositis compared to other antisynthetase antibodies .

Key Features

Notable Patterns

• ILD progression: Anti-PL7-associated ILD often presents as nonspecific interstitial pneumonia (NSIP) or organizing pneumonia (OP) .

• Overlap syndromes: Co-occurrence with anti-Ro52 (63% of cases) and scleroderma-like symptoms .

Diagnostic Methods

Anti-PL7 detection relies on:

1. ELISA: Commercial kits (e.g., Human anti-PL7 ELISA) use a sandwich assay with HRP-conjugated antibodies (detection limit: 450 nm) .

2. Immunodot/Western blot: Confirms specificity using recombinant ThrRS antigens .

3. Clinical criteria: Requires ≥1 ASS symptom (e.g., ILD, myositis) and antibody positivity .

Prognostic Implications

Serological and Radiological Features

• CD16+CD56+ (NK) cells: Reduced in anti-PL7 patients (p < 0.01) .

• HRCT patterns: NSIP-OP (37.8%), NSIP (34.2%), OP (22.5%) .

Treatment Outcomes

Emerging Insights

• COVID-19 severity: Anti-PL7+ patients had higher radiological scores (55.6% vs. 26.3% in negatives; p = 0.019) .

• Genetic factors: HLA-DRB1*03:01 and *11:01 alleles are linked to anti-PL7 susceptibility .